Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00383123 · ClinicalTrials.gov registry record · Phase 3
Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,327
- Enrollment target
NCT00383123 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 3,327 participants.
The verdict
NCT00383123, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,327 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two influenza vaccines (Fluzone and Fluarix) in terms of the immune response elicited and safety with a six month follow-up after first vaccination. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Interventions
- BIOLOGICAL Fluzone
- BIOLOGICAL Fluarix™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,327 participants |
| Start Date | 2006-11-02 |
| Est. Completion | 2007-10-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00383123
The ClinicalTrials.gov registry entry for NCT00383123 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,327 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluzone is the first listed.
NCT00383123 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00383123 about?
NCT00383123 is a clinical study titled "Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children". The purpose of this study is to compare two influenza vaccines (Fluzone and Fluarix) in terms of the immune response elicited and safety with a six month follow-up after first vaccination. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
What is the current status of trial NCT00383123?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,327 participants. The study started on 2006-11-02. Estimated completion is 2007-10-19.
What interventions are being tested in trial NCT00383123?
The interventions under investigation include: Fluzone (BIOLOGICAL), Fluarix™ (BIOLOGICAL).
Who is sponsoring clinical trial NCT00383123?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.